BackInVivo Therapeutics Holdings Overview

InVivo Therapeutics Holdings Current Cash

InVivo Therapeutics Holdings's current cash is $8.6M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$8.58M
↓ 19.02% YoYΔ $-2.02M vs prior year quarter

Peer trimmed avg / median

Loading

InVivo Therapeutics Holdings Current Cash History

Loading

InVivo Therapeutics Holdings vs. peers: Current Cash Comparison

Loading

InVivo Therapeutics Holdings Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

InVivo Therapeutics Holdings (NVIV) FAQ

The latest current cash for NVIV is $8.6M as of September 2023. That compares with $11M in the prior-year period — down 19.0% year over year. Investors often review this figure alongside InVivo Therapeutics Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, NVIV's current cash moved from $11M to $8.6M — a 19.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in InVivo Therapeutics Holdings's operating scale or balance-sheet position.

A current cash figure of $8.6M for NVIV is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NVIV's current cash ($8.6M), review year-over-year change from $11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack InVivo Therapeutics Holdings's current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.